NASDAQ NMS - GLOBAL MARKET · PGEN
+4.05% · +$0.2800 · Vol 5.8M
Market closed · last close 4:00 PM ET · price as of 19:45:41 ET
Precigen Inc

Precigen Inc

Biotechnology
$7.19
Card
Relationship Map

Veridion Score

BETAHIGH CONF · 6/6 factorsMethodology
PGEN
Precigen Inc
Fri Aug 7 · market closed · Markets closed · resumes Mon 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

51/ 100
Veridion Score
NEUTRAL · HIGH confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6/6 factors with data · Fri Aug 7 · market closed · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is PGEN moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading PGEN catalysts
About Precigen Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2013
Employees
47
Country
US

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$7.05
Day high
$7.26
Day low
$6.93
Previous close
$6.91
52W high
$7.26
-0.96% from high
52W low
$1.74
99% of range
Market cap
$2.5B
EPS
$-1.1200
Beta
1.40
Shares out
358M
Volume
5.8M
1.11× rel vol
Avg volume
5.2M
VWAP
$7.14
Price history computed in-house
1W
+14.67%
1M
+30.02%
3M
+70.78%
1Y
+303.93%
YTD
+72.01%
SMA 50 $5.20 · above
SMA 200 $4.36 · above
52W position 99%

PGEN overview

Veridion Score
51
6 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around PGEN.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading PGEN Form 4 filings
Public disclosures

Congress activity in PGEN

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for PGEN in the cached public ledger.

Federal contracts

PGEN contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for PGEN in this window.
Lobbying spend

PGEN lobbying filings, year to date.

Registered lobbying filings matched to Precigen Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for PGEN in this window.
Loading news for PGEN
Analyst ratings
Sovereign unlock shows live analyst consensus for PGEN.
Options
Sovereign unlock shows live options positioning for PGEN.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.